PolandPoland

Actavis and Bioton set out to conquer diabetes market

31.01.2012

Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that they have formed a joint venture company for the development and registration of insulins, including analogue insulins. Bioton will do all the heavy lifting, means developing and manufacturing the insulin products, while Actavis, which has roots in Iceland, will sell them more or less all over the world. Only in Bioton's backwater Poland, will each company will offer the insulin under their respective brands. Actavis will invest €55m, of which €22.5m was splashed out at the signing of the contract on Monday. Actavis' CEO Claudio Albrecht sees great potential in the world market for insulin drugs, which amasses revenues of currently €12b and is expected to grow in double digits over the next years. "We hope to be the first to launch a biosimilar insulin", Albrecht told Reuters, a news agency. Actavis has plans beyond insulin, though. He announced to launch a biosimilar for bestselling drugs every month during the first eight months of 2012.

PolandPoland

08.03.2010

Warsaw – Polish tissue-engineering specialist Euroimplant S.A. has received permission to build a new research and production facility in Klaudyn near Warsaw. The company said it is currently in talks with several investors who...

PolandPoland

01.02.2010

Warsaw – Polish pharmaceutical firm Polpharma has sought approval for its acquisition of parts of Polish blue-chip Bioton S.A. Polpharma made the bid on the last day of 2009. The case is pending. In November 2009, Bioton signed a...

PolandPoland

01.02.2010

Warsaw – Researchers at the Polish Academy of Sciences have shed new light on how plants adapt their flowering to climate. According to the team under Szymon Swiezewsk (Nature 462, 799-802), the plants use a kind of cold sensor...

PolandPoland

09.11.2009

Warsaw – Janusz Guy, chief executive of Polish insulin manufacturer Bioton SA, has stepped down shortly before the firm is due to present its Q3 results. He will be replaced by Slawomir Ziegert, who joined Bioton from competitor...

PolandPoland

20.09.2009

Warsaw – Polish insulin, antibiotics, and biosimilar producer Bioton SA has doubled its second-quarter net loss to PLN39m (–EUR9.3m) because sales fell by 8% in the period from April to June. The company, which is restructuring...

PolandPoland

19.09.2009

Kraków – The Polish biotechnology market has been shrinking in the last two years, according to a report just released by the Kraków-based consultancy PMR. Polish biotech industry sales fell by 2% in 2008 to PLN607m (EUR173m)...

PolandPoland

21.07.2009

Warsaw - Poland has violated its obligation towards the EU in regard to GMOs, the European Court of Justice has declared in Luxembourg. Poland, which is fighting to become a GMO free country, had been in dispute with the European...

PolandPoland

11.07.2009

Warsaw – Polish insulin maker Bioton has bounced back. After incurring a $6m loss in the first quarter of this year, (see Eurobio­techNews 5-6/2009), the company announced at the beginning of July that it was issuing €11.5m in...

PolandPoland

10.07.2009

Warsaw – Polish insulin maker Bioton SA has bounced back. After incurring a $6m loss in the first quarter of this year the company announced yesterday that it has signed an exclusive supply and distribution agreement with German...

PolandPoland

29.04.2009

Warsaw/Washington – The US Department of Agriculture (USDA) has criticised the draft law on genetically modified organisms (GMOs) that Poland recently submitted to the European Commission. The rules defined in the law “will...

Displaying results 21 to 30 out of 108

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-poland/browse/2/article/actavis-and-bioton-set-out-to-conquer-diabetes-market.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.22 EUR0.00%
  • ACTELION111.20 CHF0.00%
  • ADDEX3.98 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.22 EUR0.00%
  • ACTELION111.20 CHF0.00%

TOP

  • SANTHERA98.35 CHF64.2%
  • BB BIOTECH141.00 EUR9.0%
  • EPIGENOMICS3.37 EUR5.3%

FLOP

  • WILEX2.25 EUR-16.7%
  • MOLOGEN7.38 EUR-13.2%
  • BIOFRONTERA2.40 EUR-10.4%

TOP

  • SANTHERA98.35 CHF4310.3%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.55 EUR-67.3%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 30.08.2014


Current issue

All issues

Product of the week

Products